A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Robin L JonesSant P ChawlaSteven AttiaPatrick SchöffskiHans GelderblomBartosz ChmielowskiAxel Le CesneBrian A Van TineJonathan C TrentShreyaskumar PatelAndrew J WagnerRashmi ChughJohn W HeyburnSusan C WeilWenquan WangKert VieleRobert G MakiPublished in: Cancer (2019)
Ontuxizumab plus G/D showed no enhanced activity over chemotherapy alone in soft-tissue sarcomas, whereas the safety profile of the combination was consistent with G/D alone.